



Phenotypic Approaches in Drug Discovery

Wednesday 18 March 2015

SCI, London, UK

Organised by SCI's Fine Chemicals Group



Phenotypic Approaches in Drug Discovery



Wednesday 18 March 2015, SCI, London, UK

Synopsis

It has been suggested that phenotypic screening is more successful for discovering novel drugs than target-based approaches, especially for understanding the full pharmacology of drug actions. This meeting will introduce phenotypic screening with some of the recent changes in its use, covering the benefits and issues in this area from a range of talks including case studies.

Sponsorship & Exhibition

If you are interested in sponsoring or exhibiting at this event, please contact jacqui.colgate@soci.org for further information and costs.

Organisers

Dr Adrian Longstaff, Syngenta

Dr Nat Monck, Evotec

Dr Joanne Pinder, Vertex Pharmaceuticals

Registration

Early bird rate before 6 February 2015

SCI Member - £100, Student Member - £35, Non-Member - £135

Subsidised member - £65

Standard rate from 6 February 2015

SCI Member - £120, Student Member - £45, Non-Member - £165

Subsidised member - £80

For further details please contact:

SCI Conference Department

14/15 Belgrave Square,

London, SW1X 8PS

T: +44 (0) 20 7598 1561

E: conferences@soci.org

W: www.soci.org/events

Programme

The cellular uptake of pharmaceutical drugs is carrier-mediated and thus a problem not of biophysics but of systems biology

Prof Douglas Kell, University of Manchester

Novel macrolide inspired macrocycles, the rule breakers for "hard targets", identified by phenotypic screening

Dr Mihailo Banjanac, Fidelity
Phenotypic screening using human primary cell based assays

Dr Jeroen DeGroot, BioFocus

Zebrafish phenotypic screens for anti-inflammatory (or pro-resolution) drug discovery

Prof Steve Renshaw, University of Sheffield

A chemogenomic approach to elucidating a mechanism for directing stem cell differentiation

Dr Robert Owen, Pfizer

In silico approaches to support mode-of-action analysis using chemical and biological data

Dr Andreas Bender, University of Cambridge

Chemical Proteomics: a multifaceted tool in drug discovery

Prof Edward Tate

Integrating phenotypic screens with in vivo imaging and Reverse Phase Protein Array technologies to advance translation

Dr Neil Carragher, Edinburgh Cancer Research Centre

With thanks to our Sponsors

